5-(2,5-Dioxo-4,4-diphenyl-imidazolidin-1-yl)-pentanoic acid | 41510-54-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 5-(2,5-Dioxo-4,4-diphenyl-imidazolidin-1-yl)-pentanoic acid
• 英文别名: 3-(4-Carboxybutyl)5,5-diphenylhydantoin；5-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)pentanoic acid
• CAS: 41510-54-7
• 化学式: C₂₀H₂₀N₂O₄
• 分子量: 352.39
• InChiKey: IIOGHFGMYZHJPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  86.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• A method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays
  申请人：Baker Instruments Corporation

  公开号：EP0062277A1

  公开（公告）日：1982-10-13

  A highly sensitive, immunoassay method for determining the amount of an analyte in a sample containing a known analyte in an unknown concentration is provided. Said sample, a polypeptide-labeled analog of the analyte, an antibody specific for said analyte, a polypeptide partner capable of non-covalently binding with the polypeptide-labeled analyte to form a complex having catalytic activity, and a substrate capable of being converted to a reporter molecule by the catalytic activity of said complex are brought together in a medium. The polypeptide-labeled analyte analog is capable of competitively binding to the antibody and the polypeptide partner, the antibody inhibiting the formation of a catalytically active complex in the absence of analyte, and the concentrations of the antibody, polypeptide partner and polypeptide-labeled analyte are such as to cause varying amounts of analyte, to be directly related to the conversion of the substrate to the reporter molecule. Conversion of the substrate to the reporter molecule is then determined, and compared to conversions of substrate to reporter molecule obtained with known concentrations of the analyte.

  本发明提供了一种高灵敏度的免疫测定方法，用于测定含有未知浓度已知分析物的样品中分析物的含量。将所述样品、多肽标记的分析物类似物、针对所述分析物的特异性抗体、能够与多肽标记的分析物非共价结合形成具有催化活性的复合物的多肽伙伴，以及能够在所述复合物的催化活性作用下转化为报告分子的底物一起置于培养基中。多肽标记的分析物类似物能够竞争性地与抗体和多肽伙伴结合，抗体在没有分析物的情况下抑制具有催化活性的复合物的形成，抗体、多肽伙伴和多肽标记的分析物的浓度使分析物的量变化与底物向报告分子的转化直接相关。然后测定底物到报告分子的转化率，并与已知浓度的分析物得到的底物到报告分子的转化率进行比较。
• Method of preparing biologically active reagents from succinimide-containing polymers, analytical element and methods of use
  申请人：Johnson & Johnson Clinical Diagnostics, Inc.

  公开号：EP0496473A2

  公开（公告）日：1992-07-29

  Biologically active reagents are prepared from particles of copolymers having highly active succinimide groups. The reagents are prepared by covalently attaching biologically active substances, for example antibodies, to the particles, directly or indirectly through amide groups by displacement of highly active succinimide groups on the particle surface. These reagents are used to advantage in analytical elements, methods for the detection of specific binding ligands (such as immunological species) and immunoassays, and in purification methods such as affinity chromatography.

  生物活性试剂由具有高活性琥珀酰亚胺基团的共聚物颗粒制备而成。这些试剂的制备方法是通过酰胺基团置换颗粒表面的高活性琥珀酰亚胺基团，将生物活性物质（如抗体）直接或间接地共价连接到颗粒上。这些试剂在分析元件、特定结合配体（如免疫物种）的检测方法、免疫测定以及亲和层析等纯化方法中得到了广泛应用。
• Drug hapten analogues for immunoassays
  申请人：Johnson & Johnson Clinical Diagnostics, Inc.

  公开号：EP0517325A2

  公开（公告）日：1992-12-09

  The invention is directed to new drug hapten analogues comprising: (A) an active ester group; (B) a drug hapten nucleus selected from a hydantoin nucleus or a barbiturate nucleus and (C) a linking chain linking the 3-position of the drug hapten nucleus to the active ester group.

  本发明涉及新的药物合剂类似物，包括 (A) 一个活性酯基； (B) 选自 hydantoin 核或巴比妥酸核的药物合酶核，以及 (C) 连接药物合酶核的 3 位与活性酯基的连接链。
• Labeled drug hapten analogues for immunoassays
  申请人：Johnson & Johnson Clinical Diagnostics, Inc.

  公开号：EP0517326A2

  公开（公告）日：1992-12-09

  The invention is directed to labeled drug hapten analogues comprising: (A) a label, of the type used in immunoassays, having an amine or sulfhydryl group; (B) a drug hapten nucleus selected from barbiturates or hydantoins and (C) a linking chain linking the 3-position of the drug hapten nucleus to the label through a carbonyl bridge.

  本发明涉及标记的药物合生元类似物，包括 (A) 用于免疫测定的标签，具有胺或巯基； (B) 选自巴比妥酸盐或海因的药物合酶核，以及 (C) 通过羰基桥将药物合价核的 3 位与标签连接的连接链。
• LIPOSOME IMMUNOASSAY REAGENT AND METHOD
  申请人：COOPER-LIPOTECH, INC.

  公开号：EP0215027A1

  公开（公告）日：1987-03-25